ZURICH (Reuters) – Novartis won European approval for its gene therapy Zolgensma for the hereditary disease spinal muscular atrophy (SMA), the Swiss drugmaker said on Tuesday, adding it is in talks over price with countries in hopes of a quick launch. The Euro... More »
ZURICH (Reuters) – Swiss drugmaker Novartis on Monday said it is jettisoning what it had hoped would be a billion-dollar-selling asthma drug, fevipiprant, from its development program after the medicine failed another set of key trials. The drug’s star fell in... More »
ZURICH (Reuters) – Swiss drugmaker Novartis (NOVN.S) is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co (MDCO.O) as it challenges cardiovascular medicines from Amgen Inc (AMGN.O), Sanofi (SASY.PA) and Regeneron Pharmace... More »
(The Nov 16 story corrects to clarify in second graph that patients will be infused by a healthcare provider.) By John Miller and Carl O’Donnell (Reuters) – Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug, Adakveo, making ... More »
ZURICH (Reuters) – Novartis said on Sunday that Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose its drug over Pfizer’s blockbuster Ibrance. Kisqali plus t... More »
ZURICH (Reuters) – Novartis (NOVN.S) plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker’s decision to delay informing regulators until after the treatment’s ap... More »
VIENNA (Reuters) – An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from tests of its gene therapy Zolgensma had been manipulated. Novarti... More »
ZURICH (Reuters) – Novartis’s heart failure drug Entresto failed a trial in a new use, the Swiss drugmaker said on Monday, calling into question billions of dollars in potential revenue and taking the shine off one of the company’s biggest growth prospects. Th... More »
ZURICH/NEW YORK, (Reuters) – Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million. The... More »
NEW YORK (Reuters) – When Malachi Anderson was diagnosed with a rare and often deadly disease called spinal muscular atrophy (SMA) as an infant nearly four years ago, his parents Tina and Torence had a decision to make. In years past, many of the babies born w... More »
(Reuters) – Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into whether a second trial death could be related to the treatment. Novar... More »
(Reuters) – The U.S. Food and Drug Administration on Friday approved Novartis AG’s combination therapy to treat an aggressive type of thyroid cancer. The therapy, which uses Novartis’ Tafinlar and Mekinist, was approved to treat anaplastic thyroid cancer that ... More »
FILE PHOTO: Swiss drugmaker Novartis’ logo is seen at the company’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) – Novartis’s (NOVN.S) new Chief Executive Vas Narasimhan is remaking ... More »
FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. REUTERS/Arnd Wiegmann/File Photo (Reuters) – Switzerland’s Novartis AG (NOVN.S) is preparing to auction its U.S. generic pill business, loo... More »
FILE PHOTO: Swiss drugmaker Novartis’ logo is seen at the company’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann ZURICH (Reuters) – The U.S. Food and Drug Administration has granted priority review for Novartis... More »
FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. REUTERS/Arnd Wiegmann/File Photo (Reuters) – California’s top court on Thursday opened the door for consumers to sue Novartis AG and other ... More »
Novartis on Monday said the U.S. Food and Drug Administration has granted breakthrough therapy status to the combination of Tafinlar and Mekinist to treat patients with BRAF V600-positive stage III melanoma following surgery. More »
Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group. More »
Novartis (NOVN.S) CEO Joe Jimenez will step down on Feb. 1 and hand over to drug development chief Vas Narasimhan to decide the fate of $50 billion in assets and make good on a pledge to return the Swiss company to sales growth. More »
Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine's limited benefits. More »
Swiss drugmaker Novartis on Monday said it had won European approval for its biosimilar version of Roche’s blockbuster Rituxan as the crosstown rivals go head-to-head on a drug to treat blood cancers and immunological diseases. More »
FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. REUTERS/Arnd Wiegmann/File Photo South Korea’s antitrust regulator said it would fine Novartis’ local unit 500 million won ($444,089) for a... More »
FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. REUTERS/Arnd Wiegmann/File Photo Novartis AG on Wednesday said the U.S. Food and Drug Administration (FDA) has agreed to accelerate its rev... More »
The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January 25, 2017. REUTERS/Arnd Wiegmann Swiss drugmaker Novartis’s drugs Tafinlar and Mekinist edged closer to approval in Europe to be used together against a type of lu... More »
The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January 25, 2017. REUTERS/Arnd Wiegmann The U.S. Food and Drug Administration (FDA) has granted priority review to Novartis drug Zykadia as a first-line treatment for som... More »
The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel, Switzerland October 22, 2013. REUTERS/Arnd Wiegmann/File Photo Swiss drugmaker Novartis’s bid to bolster its eye drug portfolio suffered a setback on Monday when it announced combining ... More »
A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash/File Photo An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young a... More »
The Google logo adorns the entrance of Google Germany headquarters in Hamburg, Germany July 11, 2016. Picture taken July 11, 2016. REUTERS/Morris Mac Matzen Novartis has abandoned a 2016 goal to start testing its autofocus contact lens on people, though it sai... More »
The logo of Swiss pharmaceutical company Novartis is seen on its headquarters building in Basel, Switzerland October 27, 2015. REUTERS/Arnd Wiegmann Drugmaker Novartis (NOVN.S) is considering to sell its struggling Alcon eye care division, its chairman said in... More »
A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash/File Photo Novartis’s investigational drug PKC 412 won U.S. Food and Drug Administration priority review, the Swiss drugmaker said on Monday, keeping up mom... More »
Roche tablets are seen in this photo illustration shot January 18, 2016. REUTERS/Dado Ruvic/File Photo The spotlight on finding a cancer cure has spurred improvements in systems to collect and analyze oncology data, but efforts to track patients with other dis... More »
The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel, Switzerland October 22, 2013. REUTERS/Arnd Wiegmann/File Photo Novartis’s psoriasis drug Cosentyx showed long-term efficacy in keeping patients’ skin clear, the Swiss drugmaker said on ... More »
A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash/File Photo Novartis’s investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease v... More »
A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash/File Photo Novartis on Monday intensified its bid to convince doctors to prescribe its heart failure drug Entresto, releasing an analysis that concluded the... More »
ZURICH Novartis took its campaign to invigorate sluggish sales of its new heart-failure medicine Entresto to a U.S. cardiologists meeting on Saturday, telling attendees that even clinically stable patients can benefit from the drug. Novartis, which forecasts E... More »
ZURICH Drug companies have taken too great a share of the benefits of new drug treatments but are moving to different models involving sharing more with health systems and insurers, the head of Swiss-based Novartis was quoted saying on Sunday. “We need to tran... More »
ZURICH Novartis’ phase III study for its acute myeloid leukemia (AML) drug showed it improved overall survival by 23 percent for patients with FLT3 mutations, the Swiss drugmaker said on Sunday. Basel-based Novartis said the study was the first large controlle... More »
ZURICH Swiss drugmaker Novartis said the latest findings from a study on its newest therapy for two kinds of blood cancer track earlier results, bolstering its confidence in a 2017 U.S. regulatory submission. Novartis is testing CTL019, its investigational chi... More »
Novartis AG said on Friday it received the U.S. Food and Drug Administration’s regular approval for a drug combination to treat an aggressive form of skin cancer. The FDA approved Tafinlar and Mekinist for treatment of metastatic melanoma based on two years ov... More »
A new Novartis AG drug to treat heart failure should cost 17 percent less than its list price of $4,560 per year to keep health costs in line with growth in the overall U.S. economy, according to the nonprofit ICER. In a draft report released on Friday, the Bo... More »
ZURICH Novartis plans the first human tests next year of a “smart” contact lens it is developing with Google designed to help restore the eye’s natural autofocus. “This project is progressing well,” Novartis Chief Executive Joe Jimenez told Swiss newspaper Le ... More »
